logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5662.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5662.produseast1
Showing 1 - 5 of 5 Items
Showing 1 - 5 of 5 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Conference Material
|
Abstract

Once-weekly repurposed fosravuconazole versus daily itraconazole, with surgery, in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial

Fahal AH, Ahmed ES, Bakhiet SM, Bakheet OE, Fahal LA,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
INTRODUCTION
Treatment options for the highly neglected fungal tropical disease eumycetoma are limited and poorly adapted to patients’ contexts, with surgery often required. The firs...
Conference Material
|
Slide Presentation
Conference Material
|
Slide Presentation
Conference Material
|
Abstract
Journal Article
|
Research

Once-weekly repurposed fosravuconazole versus daily itraconazole, with surgery, in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial

Fahal AH, Ahmed ES, Bakhiet SM, Bakheet OE, Fahal LA,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024

Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial

Solomos A, Musa AM, Mbui J, Mohammed R, Olobo J,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023

Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial

Solomos A, Musa AM, Mbui J, Mohammed R, Olobo J,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
INTRODUCTION
The parasitic disease visceral leishmaniasis (VL) is most commonly caused by Leishmania donovani in eastern Africa, currently the region with highest burden worldwide. C...

Paromomycin and miltefosine combination as an alternative to treat patients with visceral leishmaniasis in Eastern Africa: A randomized, controlled, multicountry trial

Musa AM, Mbui J, Mohammed R, Olobo J, Ritmeijer KKD,  et al.
2022-09-27 • Clinical Infectious Diseases
2022-09-27 • Clinical Infectious Diseases
BACKGROUND
This study aimed to determine whether paromomycin plus miltefosine (PM/MF) is noninferior to sodium stibogluconate plus paromomycin (SSG/PM) for treatment of primary visce...